A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences

ABSTRACT In human immunodeficiency virus type 1 (HIV-1) subtype B infections, the emergence of viruses able to use CXCR4 as a coreceptor is well documented and associated with accelerated CD4 decline and disease progression. However, in HIV-1 subtype C infections, responsible for more than 50% of global infections, CXCR4 usage is less common, even in individuals with advanced disease. A reliable phenotype prediction method based on genetic sequence analysis could provide a rapid and less expensive approach to identify possible CXCR4 variants and thus increase our understanding of subtype C coreceptor usage. For subtype B V3 loop sequences, genotypic predictors have been developed based on position-specific scoring matrices (PSSM). In this study, we apply this methodology to a training set of 279 subtype C sequences of known phenotypes (228 non-syncytium-inducing [NSI] CCR5+ and 51 SI CXCR4+ sequences) to derive a C-PSSM predictor. Specificity and sensitivity distributions were estimated by combining data set bootstrapping with leave-one-out cross-validation, with random sampling of single sequences from individuals on each bootstrap iteration. The C-PSSM had an estimated specificity of 94% (confidence interval [CI], 92% to 96%) and a sensitivity of 75% (CI, 68% to 82%), which is significantly more sensitive than predictions based on other methods, including a commonly used method based on the presence of positively charged residues (sensitivity, 47.8%). A specificity of 83% and a sensitivity of 83% were achieved with a validation set of 24 SI and 47 NSI unique subtype C sequences. The C-PSSM performs as well on subtype C V3 loops as existing subtype B-specific methods do on subtype B V3 loops. We present bioinformatic evidence that particular sites may influence coreceptor usage differently, depending on the subtype.

[1]  J. Sleasman,et al.  Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). , 2000, AIDS.

[2]  B. Korber,et al.  A new classification for HIV-1 , 1998, Nature.

[3]  Jacques Corbeil,et al.  A new perspective on V3 phenotype prediction. , 2003, AIDS research and human retroviruses.

[4]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[5]  B. Margolin,et al.  Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. , 1997, Virology.

[6]  J. Margolick,et al.  Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study , 2000, AIDS.

[7]  E. Fenyö,et al.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.

[8]  R. Swanstrom,et al.  Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. , 2001, Virology.

[9]  J. Albert,et al.  Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.

[10]  C. Cheng‐Mayer,et al.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 gene , 1991, Nature.

[11]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[12]  P. Vernazza,et al.  Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.

[13]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[14]  M. Jensen,et al.  Predicting HIV-1 coreceptor usage with sequence analysis. , 2003, AIDS reviews.

[15]  J. Goudsmit,et al.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.

[16]  D. Purdie Statistical Methods in Medical Research, 4th edn , 2003 .

[17]  L. Stamatatos,et al.  Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability , 1993, Journal of virology.

[18]  L. Ping,et al.  Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. , 2006, Virology.

[19]  Noah G. Hoffman,et al.  Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop , 2002, Journal of Virology.

[20]  J. Margolick,et al.  Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.

[21]  A. Cann,et al.  The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism , 1992, Journal of virology.

[22]  Lynn Morris,et al.  The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C , 2003, Journal of Virology.

[23]  B. Margolin,et al.  V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability , 1993, Journal of virology.

[24]  R. Swanstrom,et al.  Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay , 1997, Journal of virology.

[25]  L. Morris,et al.  Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. , 2006, AIDS research and human retroviruses.

[26]  J. Albert,et al.  Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. , 1999, AIDS research and human retroviruses.

[27]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[28]  Ronald G. Collman,et al.  Preferential Use of CXCR4 by R5X4 Human Immunodeficiency Virus Type 1 Isolates for Infection of Primary Lymphocytes , 2005, Journal of Virology.

[29]  H. Schuitemaker,et al.  Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. , 2000, The Journal of clinical investigation.

[30]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[31]  D. Nickle,et al.  Genetic Characterization of Rebounding Human Immunodeficiency Virus Type 1 in Plasma during Multiple Interruptions of Highly Active Antiretroviral Therapy , 2003, Journal of Virology.

[32]  James I Mullins,et al.  Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy , 2004, AIDS.

[33]  T. D. Schneider,et al.  Sequence logos: a new way to display consensus sequences. , 1990, Nucleic acids research.